Maintain and improve quality of life with management of pain, edema and mobility
Subjects received intravenous DSIP (25 nmol/kg) or placebo before sleep for three consecutive nights
Treatment with RYBELSUS 7 mg and 14 mg once daily for 26 weeks resulted in a statistically significant reduction in HbA1c from baseline compared to placebo once daily (see Table 9)
Secondary efficacy outcomes included wound healing time, time required to resume normal work, constipation symptom, quality of life, and pain post operation was also evaluated
References Ali YS, Shaw I, Nie C et al (2026) Microfluidics-engineered mannitol- stabilized solid lipid nanoparticle hydrogel for enhanced topical delivery of apremilast in psoriasis therapy
these changes will come with unexpected symptoms such as changes in body odor that may contribute to the ill experience of night sweats